BNTX earnings: next report 2026-08-03, real EPS beat/miss history, analyst consensus Buy, P/E -15.68. Updated 2026-07-23.
BioNTech (BNTX) Research Hub
BioNTech (BNTX) trades on NASDAQ, DE in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 96.73 USD (-1.43%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -15.68, market cap 23.24B. This hub links to the full technical, earnings and options research available for BNTX.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, DE |
| Last close | 96.73 USD (-1.43%) |
| 52-week range | 88.2 USD – 120.33 USD |
| Trend regime | Range |
| 14-day RSI | 53 (Neutral) |
| Trailing P/E | -15.68 |
| Market cap | 23.24B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-03 |
Available research for BNTX
Covered Call on BNTX: how it works, illustrative setup around the real 96.73 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on BNTX: how it works, illustrative setup around the real 96.73 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on BNTX: how it works, illustrative setup around the real 96.73 USD price, max profit/loss, breakeven and when to use it. Educational.
BNTX technical analysis: range, last 96.73 USD, RSI 53, 52w range 88.2 USD–120.33 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is BNTX in?
BioNTech (BNTX) is classified under Healthcare (Biotechnology), listed on NASDAQ, DE.
Is BNTX in an uptrend or downtrend?
As of 2026-09-11, BNTX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is BNTX's trailing P/E ratio?
BNTX's trailing P/E is -15.68, with a market cap of 23.24B. See the earnings research page for full valuation detail.
When does BNTX next report earnings?
BNTX is next scheduled to report earnings on 2026-08-03, with a consensus EPS estimate of -2.39866 USD.